miR‐21‐5p, miR‐141‐3p, and miR‐205‐5p levels in urine—promising biomarkers for the identification of prostate and bladder cancer

Background Early detection of cancers improves patients’ survival and decreases the treatment cost. Unfortunately, the current methods for diagnosis of bladder and prostate cancers, two most common urothelial malignancies, suffer from a low sensitivity and specificity. MicroRNAs, as a group of endog...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Prostate Jg. 79; H. 1; S. 88 - 95
Hauptverfasser:	Ghorbanmehr, Nassim, Gharbi, Sedigheh, Korsching, Eberhard, Tavallaei, Mahmood, Einollahi, Behzad, Mowla, Seyed Javad
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Wiley Subscription Services, Inc 01.01.2019
Schlagworte:	Aged Aged, 80 and over Benign Biomarkers Biomarkers, Tumor - genetics Biomarkers, Tumor - urine Bladder Bladder cancer Data processing Diagnosis Gene expression Gene Expression Regulation, Neoplastic Humans Hyperplasia Male MicroRNAs MicroRNAs - genetics MicroRNAs - urine Middle Aged miRNA miR‐141‐3p miR‐205‐5p miR‐21‐5p Patients Prostate cancer Prostatic Neoplasms - diagnosis Prostatic Neoplasms - genetics Prostatic Neoplasms - urine Statistical analysis Tumors Urinary Bladder Neoplasms - diagnosis Urinary Bladder Neoplasms - genetics Urinary Bladder Neoplasms - urine Urine urothelial cancer prostate cancer urothelial cancer miR-141-3p miR-21-5p miR-205-5p
ISSN:	0270-4137, 1097-0045, 1097-0045
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Background Early detection of cancers improves patients’ survival and decreases the treatment cost. Unfortunately, the current methods for diagnosis of bladder and prostate cancers, two most common urothelial malignancies, suffer from a low sensitivity and specificity. MicroRNAs, as a group of endogenously produced non‐coding RNAs, regulate gene expression and their expression is observed to be altered in many cancers and cancer progression phenomena. The remarkable stability of microRNAs in biofluids and their unique expression pattern in different pathological conditions make them an appealing, noninvasive diagnostic method in cancer diagnosis. Our objective is to identify microRNAs as biomarkers in urine samples of bladder and prostate cancers to improve the existing diagnostic methods in this field. Materials and Methods In this study, urine samples from 110 men with either bladder (n = 45) or prostate (n = 23) cancer, benign prostatic hyperplasia (n = 22) and healthy controls (n = 20) were collected. qPCR was used to evaluate the expression level of miR‐21‐5p, miR‐141‐3p, and miR‐205‐5p in these samples. The sensitivity and specificity of these microRNAs were determined using ROC curve analysis. Results The analysis of the data revealed that miR‐21‐5p, miR‐141‐3p, and miR‐205‐5p are differentially expressed in urine of bladder and prostate cancer patients. All these three microRNAs were upregulated in these samples and they were also able to differentiate benign prostatic hyperplasia from malignant cases. The statistical analyses revealed a good specificity for each individual microRNA. Conclusion The results show that these three urine‐based microRNAs might be a good choice to implement a specific and non‐invasive diagnostic tool for bladder and prostate cancer. The expression pattern of all three microRNAs was particularly useful to distinguish benign and invasive tumors in prostate cases. From the patients’ perspective the improvement of the diagnostic situation is awaited eagerly.
AbstractList	Early detection of cancers improves patients' survival and decreases the treatment cost. Unfortunately, the current methods for diagnosis of bladder and prostate cancers, two most common urothelial malignancies, suffer from a low sensitivity and specificity. MicroRNAs, as a group of endogenously produced non-coding RNAs, regulate gene expression and their expression is observed to be altered in many cancers and cancer progression phenomena. The remarkable stability of microRNAs in biofluids and their unique expression pattern in different pathological conditions make them an appealing, noninvasive diagnostic method in cancer diagnosis. Our objective is to identify microRNAs as biomarkers in urine samples of bladder and prostate cancers to improve the existing diagnostic methods in this field.BACKGROUNDEarly detection of cancers improves patients' survival and decreases the treatment cost. Unfortunately, the current methods for diagnosis of bladder and prostate cancers, two most common urothelial malignancies, suffer from a low sensitivity and specificity. MicroRNAs, as a group of endogenously produced non-coding RNAs, regulate gene expression and their expression is observed to be altered in many cancers and cancer progression phenomena. The remarkable stability of microRNAs in biofluids and their unique expression pattern in different pathological conditions make them an appealing, noninvasive diagnostic method in cancer diagnosis. Our objective is to identify microRNAs as biomarkers in urine samples of bladder and prostate cancers to improve the existing diagnostic methods in this field.In this study, urine samples from 110 men with either bladder (n = 45) or prostate (n = 23) cancer, benign prostatic hyperplasia (n = 22) and healthy controls (n = 20) were collected. qPCR was used to evaluate the expression level of miR-21-5p, miR-141-3p, and miR-205-5p in these samples. The sensitivity and specificity of these microRNAs were determined using ROC curve analysis.MATERIALS AND METHODSIn this study, urine samples from 110 men with either bladder (n = 45) or prostate (n = 23) cancer, benign prostatic hyperplasia (n = 22) and healthy controls (n = 20) were collected. qPCR was used to evaluate the expression level of miR-21-5p, miR-141-3p, and miR-205-5p in these samples. The sensitivity and specificity of these microRNAs were determined using ROC curve analysis.The analysis of the data revealed that miR-21-5p, miR-141-3p, and miR-205-5p are differentially expressed in urine of bladder and prostate cancer patients. All these three microRNAs were upregulated in these samples and they were also able to differentiate benign prostatic hyperplasia from malignant cases. The statistical analyses revealed a good specificity for each individual microRNA.RESULTSThe analysis of the data revealed that miR-21-5p, miR-141-3p, and miR-205-5p are differentially expressed in urine of bladder and prostate cancer patients. All these three microRNAs were upregulated in these samples and they were also able to differentiate benign prostatic hyperplasia from malignant cases. The statistical analyses revealed a good specificity for each individual microRNA.The results show that these three urine-based microRNAs might be a good choice to implement a specific and non-invasive diagnostic tool for bladder and prostate cancer. The expression pattern of all three microRNAs was particularly useful to distinguish benign and invasive tumors in prostate cases. From the patients' perspective the improvement of the diagnostic situation is awaited eagerly.CONCLUSIONThe results show that these three urine-based microRNAs might be a good choice to implement a specific and non-invasive diagnostic tool for bladder and prostate cancer. The expression pattern of all three microRNAs was particularly useful to distinguish benign and invasive tumors in prostate cases. From the patients' perspective the improvement of the diagnostic situation is awaited eagerly. Early detection of cancers improves patients' survival and decreases the treatment cost. Unfortunately, the current methods for diagnosis of bladder and prostate cancers, two most common urothelial malignancies, suffer from a low sensitivity and specificity. MicroRNAs, as a group of endogenously produced non-coding RNAs, regulate gene expression and their expression is observed to be altered in many cancers and cancer progression phenomena. The remarkable stability of microRNAs in biofluids and their unique expression pattern in different pathological conditions make them an appealing, noninvasive diagnostic method in cancer diagnosis. Our objective is to identify microRNAs as biomarkers in urine samples of bladder and prostate cancers to improve the existing diagnostic methods in this field. In this study, urine samples from 110 men with either bladder (n = 45) or prostate (n = 23) cancer, benign prostatic hyperplasia (n = 22) and healthy controls (n = 20) were collected. qPCR was used to evaluate the expression level of miR-21-5p, miR-141-3p, and miR-205-5p in these samples. The sensitivity and specificity of these microRNAs were determined using ROC curve analysis. The analysis of the data revealed that miR-21-5p, miR-141-3p, and miR-205-5p are differentially expressed in urine of bladder and prostate cancer patients. All these three microRNAs were upregulated in these samples and they were also able to differentiate benign prostatic hyperplasia from malignant cases. The statistical analyses revealed a good specificity for each individual microRNA. The results show that these three urine-based microRNAs might be a good choice to implement a specific and non-invasive diagnostic tool for bladder and prostate cancer. The expression pattern of all three microRNAs was particularly useful to distinguish benign and invasive tumors in prostate cases. From the patients' perspective the improvement of the diagnostic situation is awaited eagerly. BackgroundEarly detection of cancers improves patients’ survival and decreases the treatment cost. Unfortunately, the current methods for diagnosis of bladder and prostate cancers, two most common urothelial malignancies, suffer from a low sensitivity and specificity. MicroRNAs, as a group of endogenously produced non‐coding RNAs, regulate gene expression and their expression is observed to be altered in many cancers and cancer progression phenomena. The remarkable stability of microRNAs in biofluids and their unique expression pattern in different pathological conditions make them an appealing, noninvasive diagnostic method in cancer diagnosis. Our objective is to identify microRNAs as biomarkers in urine samples of bladder and prostate cancers to improve the existing diagnostic methods in this field.Materials and MethodsIn this study, urine samples from 110 men with either bladder (n = 45) or prostate (n = 23) cancer, benign prostatic hyperplasia (n = 22) and healthy controls (n = 20) were collected. qPCR was used to evaluate the expression level of miR‐21‐5p, miR‐141‐3p, and miR‐205‐5p in these samples. The sensitivity and specificity of these microRNAs were determined using ROC curve analysis.ResultsThe analysis of the data revealed that miR‐21‐5p, miR‐141‐3p, and miR‐205‐5p are differentially expressed in urine of bladder and prostate cancer patients. All these three microRNAs were upregulated in these samples and they were also able to differentiate benign prostatic hyperplasia from malignant cases. The statistical analyses revealed a good specificity for each individual microRNA.ConclusionThe results show that these three urine‐based microRNAs might be a good choice to implement a specific and non‐invasive diagnostic tool for bladder and prostate cancer. The expression pattern of all three microRNAs was particularly useful to distinguish benign and invasive tumors in prostate cases. From the patients’ perspective the improvement of the diagnostic situation is awaited eagerly. Background Early detection of cancers improves patients’ survival and decreases the treatment cost. Unfortunately, the current methods for diagnosis of bladder and prostate cancers, two most common urothelial malignancies, suffer from a low sensitivity and specificity. MicroRNAs, as a group of endogenously produced non‐coding RNAs, regulate gene expression and their expression is observed to be altered in many cancers and cancer progression phenomena. The remarkable stability of microRNAs in biofluids and their unique expression pattern in different pathological conditions make them an appealing, noninvasive diagnostic method in cancer diagnosis. Our objective is to identify microRNAs as biomarkers in urine samples of bladder and prostate cancers to improve the existing diagnostic methods in this field. Materials and Methods In this study, urine samples from 110 men with either bladder (n = 45) or prostate (n = 23) cancer, benign prostatic hyperplasia (n = 22) and healthy controls (n = 20) were collected. qPCR was used to evaluate the expression level of miR‐21‐5p, miR‐141‐3p, and miR‐205‐5p in these samples. The sensitivity and specificity of these microRNAs were determined using ROC curve analysis. Results The analysis of the data revealed that miR‐21‐5p, miR‐141‐3p, and miR‐205‐5p are differentially expressed in urine of bladder and prostate cancer patients. All these three microRNAs were upregulated in these samples and they were also able to differentiate benign prostatic hyperplasia from malignant cases. The statistical analyses revealed a good specificity for each individual microRNA. Conclusion The results show that these three urine‐based microRNAs might be a good choice to implement a specific and non‐invasive diagnostic tool for bladder and prostate cancer. The expression pattern of all three microRNAs was particularly useful to distinguish benign and invasive tumors in prostate cases. From the patients’ perspective the improvement of the diagnostic situation is awaited eagerly.
Author	Einollahi, Behzad Gharbi, Sedigheh Korsching, Eberhard Ghorbanmehr, Nassim Tavallaei, Mahmood Mowla, Seyed Javad
Author_xml	– sequence: 1 givenname: Nassim surname: Ghorbanmehr fullname: Ghorbanmehr, Nassim organization: Alzahra University – sequence: 2 givenname: Sedigheh orcidid: 0000-0002-9032-3908 surname: Gharbi fullname: Gharbi, Sedigheh organization: Shahid Bahonar University of Kerman – sequence: 3 givenname: Eberhard surname: Korsching fullname: Korsching, Eberhard organization: University of Münster – sequence: 4 givenname: Mahmood surname: Tavallaei fullname: Tavallaei, Mahmood organization: Baqiyatallah Medical Sciences University – sequence: 5 givenname: Behzad surname: Einollahi fullname: Einollahi, Behzad organization: Baqiyatallah University of Medical Sciences – sequence: 6 givenname: Seyed Javad surname: Mowla fullname: Mowla, Seyed Javad email: sjmowla@modares.ac.ir organization: Tarbiat Modares University
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/30194772$$D View this record in MEDLINE/PubMed
BookMark	eNp9kc1u1TAQhS1URG8LGx4AWWKDECnjv_wsUQUUqVKrAuvIdsbgkutc7ATUXZ8AsegT9klwbi5dVIiNrRl9Z3TmzAHZC0NAQp4yOGIA_PUmDumIi4rJB2TFoKkKAKn2yAp4BYVkotonByldAmQc-COyL4A1sqr4ivxa-4vb69-c5UdtXtGlZHKuRa516HY9DmrL0B5_YJ-oD3SKPuDt9U02sPbJhy_U-GGt4zeMiboh0vErUt9hGL3zVo9-CHRwdPY76hG3w02vuw4jtTpYjI_JQ6f7hE92_yH5_O7tp-OT4vTs_YfjN6eFlVzIoqtr5UQpVWWEMQxL5UxpDJTGOtTQaKOFcaW0tlI4g7VCJiutmDGucSgOyYtlbvbyfcI0tnkBi32vAw5TajkDxsuaN01Gn99DL4cphuwuUwq4KJmoM_VsR01mjV27iT4HcdX-TToDLxfA5u1TRHeHMGjnM7ZzLO32jBmGe7D14za_MWrf_1vCFslP3-PVf4a35xdnHxfNH01Htd8
CitedBy_id	crossref_primary_10_1002_kjm2_12845 crossref_primary_10_2478_fzm_2021_0009 crossref_primary_10_2217_fon_2022_0891 crossref_primary_10_1002_mgg3_1233 crossref_primary_10_3389_fcell_2021_663147 crossref_primary_10_1016_j_humgen_2022_201081 crossref_primary_10_1016_j_humgen_2022_201120 crossref_primary_10_17650_1726_9776_2024_20_1_36_43 crossref_primary_10_1016_j_bbcan_2022_188809 crossref_primary_10_1080_14737159_2019_1675515 crossref_primary_10_3390_biomedicines10112766 crossref_primary_10_1002_jgm_3184 crossref_primary_10_1007_s12094_020_02349_z crossref_primary_10_1016_j_bbrep_2025_102041 crossref_primary_10_1016_j_cca_2024_120113 crossref_primary_10_3390_ijms23073996 crossref_primary_10_1016_j_cellsig_2022_110354 crossref_primary_10_3390_pharmaceutics13030380 crossref_primary_10_1016_j_cellsig_2021_110113 crossref_primary_10_3390_cancers13225850 crossref_primary_10_3390_medicina58040529 crossref_primary_10_1016_j_prp_2020_153182 crossref_primary_10_1089_dna_2018_4529 crossref_primary_10_1142_S2737416524500625 crossref_primary_10_3390_life11101044 crossref_primary_10_1007_s00216_023_04659_x crossref_primary_10_1080_08923973_2021_1942901 crossref_primary_10_1016_j_biopha_2023_115027 crossref_primary_10_1007_s12032_023_02176_6 crossref_primary_10_3389_fonc_2022_965231 crossref_primary_10_3390_ijms21134796 crossref_primary_10_1016_j_cej_2025_159806 crossref_primary_10_1016_j_acuroe_2021_05_005 crossref_primary_10_1097_MD_0000000000019993 crossref_primary_10_3390_cancers15174357 crossref_primary_10_1016_j_cca_2025_120187 crossref_primary_10_1038_s41391_021_00353_0 crossref_primary_10_3390_ijms232012253 crossref_primary_10_1016_j_phrs_2022_106568 crossref_primary_10_1007_s11033_020_05932_3 crossref_primary_10_1016_j_lfs_2023_121773 crossref_primary_10_1111_1759_7714_14331 crossref_primary_10_3390_ijms241310846 crossref_primary_10_1007_s10528_024_10714_8 crossref_primary_10_2147_CMAR_S250829 crossref_primary_10_3390_bios14090443 crossref_primary_10_5937_jomb0_32046 crossref_primary_10_1155_2020_1796701 crossref_primary_10_2217_bmm_2020_0319 crossref_primary_10_1007_s12094_021_02653_2 crossref_primary_10_3389_fgene_2022_936305 crossref_primary_10_1080_10408363_2019_1657061 crossref_primary_10_1080_14737140_2022_2147511 crossref_primary_10_3390_ijms22084278 crossref_primary_10_2147_CMAR_S325246 crossref_primary_10_37349_etat_2025_1002301 crossref_primary_10_1016_j_ijbiomac_2021_12_141 crossref_primary_10_3390_s20216289 crossref_primary_10_1007_s10620_021_07055_6 crossref_primary_10_1016_j_acuro_2021_05_010 crossref_primary_10_3390_vetsci12070621 crossref_primary_10_1080_14728222_2023_2293750 crossref_primary_10_1016_j_csbj_2024_06_030 crossref_primary_10_1007_s11255_025_04581_4 crossref_primary_10_3389_fphar_2025_1617452 crossref_primary_10_1186_s12967_018_1760_8 crossref_primary_10_3390_cancers13235874 crossref_primary_10_1097_MD_0000000000043613 crossref_primary_10_1016_j_cellsig_2024_111297 crossref_primary_10_1007_s11864_023_01121_z crossref_primary_10_1128_MCB_00115_21 crossref_primary_10_2217_epi_2019_0275 crossref_primary_10_3390_cancers15123140 crossref_primary_10_3390_jpm10040236 crossref_primary_10_1007_s00604_024_06596_7 crossref_primary_10_4103_jcrt_jcrt_1014_21 crossref_primary_10_1016_j_wneu_2020_11_043 crossref_primary_10_1007_s13237_024_00494_2 crossref_primary_10_3390_cancers14133157 crossref_primary_10_3390_ijms23169148
Cites_doi	10.1016/j.urolonc.2010.05.008 10.1007/978-94-017-9523-4_19 10.1371/journal.pone.0018286 10.1016/j.bbrc.2009.03.077 10.1158/0008-5472.CAN-09-1448 10.1016/j.gpb.2015.02.001 10.5489/cuaj.278 10.1586/era.11.195 10.1016/j.urolonc.2007.01.019 10.1100/tsw.2011.104 10.1016/j.clgc.2012.01.001 10.1371/journal.pone.0076994 10.1007/s13277-010-0111-z 10.1073/pnas.0510565103 10.4103/0256-4947.51802 10.1371/journal.pone.0194530 10.1016/S0092-8674(04)00045-5 10.3389/fgene.2013.00150 10.2307/2531595 10.1002/ijc.27949 10.1016/j.ygyno.2008.04.033 10.1016/j.cell.2005.06.036 10.1158/0008-5472.CAN-08-1305 10.1038/bjc.2015.472 10.1073/pnas.0804549105 10.1186/1471-2296-3-19 10.1038/nrc1997 10.1158/0008-5472.CAN-07-0533 10.1038/bjc.2012.221 10.7150/jca.3.19 10.1016/j.urolonc.2009.04.019 10.7150/jca.6799 10.1148/radiol.14140184 10.1007/s13277-015-4698-y 10.1371/journal.pone.0117284 10.1186/1471-2407-14-930 10.1038/nature03702 10.1038/nri2708 10.3322/caac.21442 10.1371/journal.pone.0022570 10.1371/journal.pone.0003694 10.2353/jmoldx.2008.080067 10.1038/onc.2015.176 10.1186/s12885-015-1190-4 10.1007/s11306-012-0482-9 10.1186/1476-4598-9-12 10.1002/ijc.24390 10.1093/jnci/dju366
ContentType	Journal Article
Copyright	2018 Wiley Periodicals, Inc. 2019 Wiley Periodicals, Inc.
Copyright_xml	– notice: 2018 Wiley Periodicals, Inc. – notice: 2019 Wiley Periodicals, Inc.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TO 8FD FR3 H94 K9. P64 RC3 7X8
DOI	10.1002/pros.23714
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE Genetics Abstracts
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1097-0045
EndPage	95
ExternalDocumentID	30194772 10_1002_pros_23714 PROS23714
Genre	article Research Support, Non-U.S. Gov't Journal Article
GrantInformation_xml	– fundername: Biotech Fund, Tehran, Iran funderid: 11000/95 – fundername: Biotech Fund, Tehran, Iran grantid: 11000/95
GroupedDBID	--- .3N .GA 05W 0R~ 10A 123 1L6 1OB 1OC 1ZS 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SUPJJ SV3 TEORI UB1 V2E W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR XG1 XV2 ZZTAW ~IA ~WT .GJ .Y3 31~ 3O- 53G AAMMB AANHP AAYXX ABEML ACBWZ ACRPL ACSCC ACYXJ ADNMO AEFGJ AEYWJ AFFNX AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE ASPBG AVWKF AZFZN CITATION FEDTE HF~ HVGLF LW6 M6P O8X PALCI RIWAO RJQFR SAMSI ZGI ZXP CGR CUY CVF ECM EIF NPM 7T5 7TO 8FD FR3 H94 K9. P64 RC3 7X8
ID	FETCH-LOGICAL-c4234-d885f36457b3bb1e65fb6bb06bcfea09aba3bf64cc75ef36485e147a51bbf9fe3
IEDL.DBID	DRFUL
ISICitedReferencesCount	106
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000452144500010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0270-4137 1097-0045
IngestDate	Thu Jul 10 18:51:35 EDT 2025 Sat Nov 29 14:27:31 EST 2025 Wed Feb 19 02:36:03 EST 2025 Sat Nov 29 01:36:57 EST 2025 Tue Nov 18 22:36:15 EST 2025 Wed Jan 22 16:51:30 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	prostate cancer urothelial cancer miR-141-3p miR-21-5p miR-205-5p
Language	English
License	2018 Wiley Periodicals, Inc.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4234-d885f36457b3bb1e65fb6bb06bcfea09aba3bf64cc75ef36485e147a51bbf9fe3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0002-9032-3908
PMID	30194772
PQID	2150236138
PQPubID	1016443
PageCount	8
ParticipantIDs	proquest_miscellaneous_2101268299 proquest_journals_2150236138 pubmed_primary_30194772 crossref_primary_10_1002_pros_23714 crossref_citationtrail_10_1002_pros_23714 wiley_primary_10_1002_pros_23714_PROS23714
PublicationCentury	2000
PublicationDate	January 1, 2019
PublicationDateYYYYMMDD	2019-01-01
PublicationDate_xml	– month: 01 year: 2019 text: January 1, 2019 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Hoboken
PublicationTitle	The Prostate
PublicationTitleAlternate	Prostate
PublicationYear	2019
Publisher	Wiley Subscription Services, Inc
Publisher_xml	– name: Wiley Subscription Services, Inc
References	2010; 10 2013; 4 2011; 11 2008; 105 2008; 3 2015; 107 2013; 7 2013; 8 2012; 12 2016; 37 2012; 10 2016; 35 2013; 9 2014; 5 2000; 14 2010; 28 1988; 44 2014; 14 2008; 68 2016; 114 2008; 110 2007; 67 2009; 125 2007; 25 2010; 9 2015; 13 2009; 69 2015; 15 2015; 17 2005; 435 2015; 10 2002; 3 2006; 6 2011; 32 2008; 10 2015; 845 2011; 6 2012; 107 2009; 29 2012; 30 2018; 68 2004; 116 2012; 3 2005; 122 2015; 275 2013; 132 2009; 383 2006; 103 2018; 13 e_1_2_8_28_1 e_1_2_8_24_1 e_1_2_8_47_1 e_1_2_8_26_1 e_1_2_8_49_1 Gharbi S (e_1_2_8_33_1) 2015; 17 e_1_2_8_3_1 e_1_2_8_5_1 e_1_2_8_7_1 e_1_2_8_9_1 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_41_1 e_1_2_8_17_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_32_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_51_1 e_1_2_8_30_1 e_1_2_8_29_1 e_1_2_8_25_1 e_1_2_8_46_1 e_1_2_8_27_1 e_1_2_8_48_1 e_1_2_8_2_1 e_1_2_8_4_1 e_1_2_8_8_1 Baselli EC (e_1_2_8_6_1) 2000; 14 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_23_1 e_1_2_8_44_1 e_1_2_8_40_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_16_1 e_1_2_8_37_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_12_1 e_1_2_8_50_1
References_xml	– volume: 103 start-page: 2257 year: 2006 end-page: 2261 article-title: A microRNA expression signature of human solid tumors defines cancer gene targets publication-title: Proc Natl Acad Sci USA – volume: 68 start-page: 7 year: 2018 end-page: 30 article-title: Cancer statistics, 2018 publication-title: CA Cancer J Clin – volume: 37 start-page: 8075 year: 2016 end-page: 8082 article-title: Circulating miR‐205: a promising biomarker for the detection and prognosis evaluation of bladder cancer publication-title: Tumour Biol – volume: 14 start-page: 719 year: 2000 end-page: 729 article-title: Intravesical therapy for superficial bladder cancer publication-title: Oncology (Williston Park) – volume: 10 start-page: 411 year: 2008 end-page: 414 article-title: The emergent role of MicroRNAs in molecular diagnostics of cancer publication-title: J Mol Diagn – volume: 10 start-page: 106 year: 2012 end-page: 113 article-title: Expression of microRNAs in the urine of patients with bladder cancer publication-title: Clin Genitourin Cancer – volume: 30 start-page: 434 year: 2012 end-page: 443 article-title: Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer publication-title: Urol Oncol – volume: 105 start-page: 10513 year: 2008 end-page: 10518 article-title: Circulating microRNAs as stable blood‐based markers for cancer detection publication-title: Proc Natl Acad Sci USA – volume: 13 start-page: 17 year: 2015 end-page: 24 article-title: Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function publication-title: Genomics Proteomics Bioinformatics – volume: 116 start-page: 281 year: 2004 end-page: 297 article-title: MicroRNAs: genomics, biogenesis, mechanism, and function publication-title: Cell – volume: 44 start-page: 837 year: 1988 end-page: 845 article-title: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach publication-title: Biometrics – volume: 845 start-page: 195 year: 2015 end-page: 203 article-title: Urinary protein biomarker database: a useful tool for biomarker discovery publication-title: Adv Exp Med Biol – volume: 35 start-page: 1180 year: 2016 end-page: 1192 article-title: A microRNA code for prostate cancer metastasis publication-title: Oncogene – volume: 9 start-page: 12 year: 2010 article-title: MiR‐21: an oncomir on strike in prostate cancer publication-title: Mol Cancer – volume: 122 start-page: 6 year: 2005 end-page: 7 article-title: MiRNAs, cancer, and stem cell division publication-title: Cell – volume: 17 start-page: 494 year: 2015 end-page: 501 article-title: Identification of reliable reference genes for quantification of MicroRNAs in serum samples of sulfur mustard‐exposed veterans publication-title: Cell J (Yakhteh) – volume: 32 start-page: 179 year: 2011 end-page: 188 article-title: MicroRNA‐dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24 publication-title: Tumour Biol – volume: 14 start-page: 930 year: 2014 article-title: MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers publication-title: BMC Cancer – volume: 110 start-page: 13 year: 2008 end-page: 21 article-title: MicroRNA signatures of tumor‐derived exosomes as diagnostic biomarkers of ovarian cancer publication-title: Gynecol Oncol – volume: 4 start-page: 150 year: 2013 article-title: The detection of microRNA associated with Alzheimer's disease in biological fluids using next‐generation sequencing technologies publication-title: Front Genet – volume: 28 start-page: 401 year: 2010 end-page: 408 article-title: Molecular pathways of urothelial development and bladder tumorigenesis publication-title: Urol Oncol – volume: 68 start-page: 8164 year: 2008 end-page: 8172 article-title: MicroRNA‐21 targets a network of key tumor‐suppressive pathways in glioblastoma cells publication-title: Cancer Res – volume: 132 start-page: 2479 year: 2013 end-page: 2491 article-title: MicroRNA expression profile in a large series of bladder tumors: identification of a 3‐miRNA signature associated with aggressiveness of muscle‐invasive bladder cancer publication-title: Int J Cancer – volume: 10 start-page: 111 year: 2010 article-title: Physiological and pathological roles for microRNAs in the immune system publication-title: Nat Rev Immunol – volume: 13 start-page: e0194530 year: 2018 article-title: MicroRNA expression in serum samples of sulfur mustard veterans as a diagnostic gateway to improve care publication-title: PLoS ONE – volume: 6 start-page: e18286 year: 2011 article-title: MicroRNA expression signatures of bladder cancer revealed by deep sequencing publication-title: PLoS ONE – volume: 9 start-page: 280 year: 2013 end-page: 299 article-title: Translational biomarker discovery in clinical metabolomics: an introductory tutorial publication-title: Metabolomics – volume: 3 start-page: e3694 year: 2008 article-title: Detection of microRNA Expression in Human Peripheral Blood Microvesicles publication-title: PLoS ONE – volume: 69 start-page: 7165 year: 2009 end-page: 7169 article-title: MiR‐21: An androgen receptor–regulated microrna that promotes hormone‐dependent and hormone‐independent prostate cancer growth publication-title: Cancer Res – volume: 3 start-page: 19 year: 2002 article-title: Prostate‐specific antigen testing accuracy in community practice publication-title: BMC Fam Pract – volume: 6 start-page: 857 year: 2006 end-page: 866 article-title: MicroRNA signatures in human cancers publication-title: Nat Rev Cancer – volume: 7 start-page: 28 year: 2013 end-page: 32 article-title: A pilot study of urinary microRNA as a biomarker for urothelial cancer publication-title: Can Urol Assoc J – volume: 275 start-page: 458 year: 2015 end-page: 468 article-title: Prostate imaging reporting and data system and likert scoring system: multiparametric MR imaging validation study to screen patients for initial biopsy publication-title: Radiology – volume: 5 start-page: 182 year: 2014 end-page: 191 article-title: Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients publication-title: ‎J Cancer – volume: 11 start-page: 1103 year: 2011 end-page: 1112 article-title: Current and emerging bladder cancer urinary biomarkers publication-title: Sci World J – volume: 435 start-page: 834 year: 2005 end-page: 838 article-title: MicroRNA expression profiles classify human cancers publication-title: Nature – volume: 125 start-page: 345 year: 2009 end-page: 352 article-title: Identification of novel microRNA targets based on microRNA signatures in bladder cancer publication-title: Int J Cancer – volume: 8 start-page: e76994 year: 2013 article-title: MicroRNA profiling in prostate cancer—the diagnostic potential of urinary miR‐205 and miR‐214 publication-title: PLoS ONE – volume: 12 start-page: 87 year: 2012 end-page: 98 article-title: Urothelial cancers: using biology to improve outcomes publication-title: Expert Rev Anticancer Ther – volume: 15 start-page: 193 year: 2015 article-title: Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non‐invasive biomarker publication-title: BMC Cancer – volume: 114 start-page: 454 year: 2016 end-page: 462 article-title: A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance publication-title: Br J Cancer – volume: 25 start-page: 387 year: 2007 end-page: 392 article-title: Micro‐RNA profiling in kidney and bladder cancers publication-title: Urol Oncol – volume: 3 start-page: 19 year: 2012 end-page: 31 article-title: Promising candidate urinary MicroRNA biomarkers for the early detection of hepatocellular carcinoma among high‐risk hepatitis C virus egyptian patients publication-title: ‎J Cancer – volume: 67 start-page: 6130 year: 2007 end-page: 6135 article-title: MicroRNA expression profiling in prostate cancer publication-title: Cancer Res – volume: 107 start-page: 123 year: 2012 end-page: 128 article-title: An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer publication-title: Br J Cancer – volume: 10 start-page: e0117284 year: 2015 article-title: Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer publication-title: PLoS ONE – volume: 383 start-page: 280 year: 2009 end-page: 285 article-title: MicroRNA‐21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells publication-title: Biochem Biophys Res Commun – volume: 6 start-page: e22570 year: 2011 article-title: Comparative mRNA and microRNA expression profiling of three genitourinary cancers reveals common hallmarks and cancer‐specific molecular events publication-title: PLoS ONE – volume: 29 start-page: 134 year: 2009 end-page: 137 article-title: The accuracy of ultrasonography in the diagnosis of superficial bladder tumors in patients presenting with hematuria publication-title: Ann Saudi Med – volume: 107 start-page: 366 year: 2015 article-title: Cost‐effectiveness of prostate cancer screening: a simulation study based on ERSPC data publication-title: J Natl Cancer Inst – ident: e_1_2_8_21_1 doi: 10.1016/j.urolonc.2010.05.008 – ident: e_1_2_8_24_1 doi: 10.1007/978-94-017-9523-4_19 – ident: e_1_2_8_38_1 doi: 10.1371/journal.pone.0018286 – ident: e_1_2_8_46_1 doi: 10.1016/j.bbrc.2009.03.077 – ident: e_1_2_8_16_1 doi: 10.1158/0008-5472.CAN-09-1448 – ident: e_1_2_8_27_1 doi: 10.1016/j.gpb.2015.02.001 – ident: e_1_2_8_30_1 doi: 10.5489/cuaj.278 – volume: 17 start-page: 494 year: 2015 ident: e_1_2_8_33_1 article-title: Identification of reliable reference genes for quantification of MicroRNAs in serum samples of sulfur mustard‐exposed veterans publication-title: Cell J (Yakhteh) – volume: 14 start-page: 719 year: 2000 ident: e_1_2_8_6_1 article-title: Intravesical therapy for superficial bladder cancer publication-title: Oncology (Williston Park) – ident: e_1_2_8_4_1 doi: 10.1586/era.11.195 – ident: e_1_2_8_19_1 doi: 10.1016/j.urolonc.2007.01.019 – ident: e_1_2_8_7_1 doi: 10.1100/tsw.2011.104 – ident: e_1_2_8_47_1 doi: 10.1016/j.clgc.2012.01.001 – ident: e_1_2_8_48_1 doi: 10.1371/journal.pone.0076994 – ident: e_1_2_8_20_1 doi: 10.1007/s13277-010-0111-z – ident: e_1_2_8_14_1 doi: 10.1073/pnas.0510565103 – ident: e_1_2_8_8_1 doi: 10.4103/0256-4947.51802 – ident: e_1_2_8_12_1 doi: 10.1371/journal.pone.0194530 – ident: e_1_2_8_9_1 doi: 10.1016/S0092-8674(04)00045-5 – ident: e_1_2_8_25_1 doi: 10.3389/fgene.2013.00150 – ident: e_1_2_8_32_1 doi: 10.2307/2531595 – ident: e_1_2_8_40_1 doi: 10.1002/ijc.27949 – ident: e_1_2_8_23_1 doi: 10.1016/j.ygyno.2008.04.033 – ident: e_1_2_8_11_1 doi: 10.1016/j.cell.2005.06.036 – ident: e_1_2_8_45_1 doi: 10.1158/0008-5472.CAN-08-1305 – ident: e_1_2_8_26_1 doi: 10.1038/bjc.2015.472 – ident: e_1_2_8_43_1 doi: 10.1073/pnas.0804549105 – ident: e_1_2_8_35_1 doi: 10.1186/1471-2296-3-19 – ident: e_1_2_8_10_1 doi: 10.1038/nrc1997 – ident: e_1_2_8_41_1 doi: 10.1158/0008-5472.CAN-07-0533 – ident: e_1_2_8_29_1 doi: 10.1038/bjc.2012.221 – ident: e_1_2_8_36_1 doi: 10.7150/jca.3.19 – ident: e_1_2_8_2_1 doi: 10.1016/j.urolonc.2009.04.019 – ident: e_1_2_8_37_1 doi: 10.7150/jca.6799 – ident: e_1_2_8_50_1 doi: 10.1148/radiol.14140184 – ident: e_1_2_8_49_1 doi: 10.1007/s13277-015-4698-y – ident: e_1_2_8_42_1 doi: 10.1371/journal.pone.0117284 – ident: e_1_2_8_3_1 doi: 10.1186/1471-2407-14-930 – ident: e_1_2_8_13_1 doi: 10.1038/nature03702 – ident: e_1_2_8_44_1 doi: 10.1038/nri2708 – ident: e_1_2_8_5_1 doi: 10.3322/caac.21442 – ident: e_1_2_8_39_1 doi: 10.1371/journal.pone.0022570 – ident: e_1_2_8_28_1 doi: 10.1371/journal.pone.0003694 – ident: e_1_2_8_15_1 doi: 10.2353/jmoldx.2008.080067 – ident: e_1_2_8_18_1 doi: 10.1038/onc.2015.176 – ident: e_1_2_8_31_1 doi: 10.1186/s12885-015-1190-4 – ident: e_1_2_8_34_1 doi: 10.1007/s11306-012-0482-9 – ident: e_1_2_8_17_1 doi: 10.1186/1476-4598-9-12 – ident: e_1_2_8_22_1 doi: 10.1002/ijc.24390 – ident: e_1_2_8_51_1 doi: 10.1093/jnci/dju366
SSID	ssj0010002
Score	2.5543518
Snippet	Background Early detection of cancers improves patients’ survival and decreases the treatment cost. Unfortunately, the current methods for diagnosis of bladder... Early detection of cancers improves patients' survival and decreases the treatment cost. Unfortunately, the current methods for diagnosis of bladder and... BackgroundEarly detection of cancers improves patients’ survival and decreases the treatment cost. Unfortunately, the current methods for diagnosis of bladder...
SourceID	proquest pubmed crossref wiley
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	88
SubjectTerms	Aged Aged, 80 and over Benign Biomarkers Biomarkers, Tumor - genetics Biomarkers, Tumor - urine Bladder Bladder cancer Data processing Diagnosis Gene expression Gene Expression Regulation, Neoplastic Humans Hyperplasia Male MicroRNAs MicroRNAs - genetics MicroRNAs - urine Middle Aged miRNA miR‐141‐3p miR‐205‐5p miR‐21‐5p Patients Prostate cancer Prostatic Neoplasms - diagnosis Prostatic Neoplasms - genetics Prostatic Neoplasms - urine Statistical analysis Tumors Urinary Bladder Neoplasms - diagnosis Urinary Bladder Neoplasms - genetics Urinary Bladder Neoplasms - urine Urine urothelial cancer
Title	miR‐21‐5p, miR‐141‐3p, and miR‐205‐5p levels in urine—promising biomarkers for the identification of prostate and bladder cancer
URI	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpros.23714 https://www.ncbi.nlm.nih.gov/pubmed/30194772 https://www.proquest.com/docview/2150236138 https://www.proquest.com/docview/2101268299
Volume	79
WOSCitedRecordID	wos000452144500010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1097-0045 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0010002 issn: 0270-4137 databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB61W4S48H4ESmUEFxBpE9tJHIkLAlYcSqkWivYW2Y4trbRkq6Tl3F-AOPAL-0uYcbKpKhAS4hLZ8SS27Hl89thjgGe5rH0unIlTq-tY1ijpWmPKap8JU6dKhZvnvuwXBwdqPi8PN-DV-ixMHx9iXHAjyQj6mgRcm27vImgoKphul1PAuU3Y4si42QS23s6mR_ujF4HEPayxFEmMyroYw5PyvYuvLxuk31DmZdAarM70xv-19yZcH9Ame92zxy3YcM1tuPph8Kffge9fF7Pzsx88xUd2_JL12VRSXmBeN_XwjidZoGFL2mXUsUXDaJ3enZ_9xCqRWdAEMjrLT9t92o4hFmaILdmiHrYjBQ5gK8-ohYRww8_NkjRfyywxX3sXjqbvPr95Hw83NMQWYZiMa6UyT47MwghjUpdn3uTGJLmx3umk1EYL43NpbZE5IlSZS2Whs9QYX3on7sGkWTXuATDSJbmSTiuNczzOy1Sn3AiHADERXsgInq-HqbJD-HK6RWNZ9YGXeUXNr0IHR_B0pD3ug3b8kWp7PdrVILhYggCZ4tEIFcGTsRh7kfwounGrU6JBq54rNOQR3O-5ZKwG9WUpccYSwYvADH-pvzqcffwUUg__hfgRXEPQVvbLQNswOWlP3WO4Yr-dLLp2BzaLudoZBOEXvs8Rxg
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB5Bi6AXfgsEChjBBdTQJHYS54iAVRHbpVpa1FtkO7a00pKtsm3PfQLEgSfskzDjuKkqEBLiEtnxJLbs-fk8tscALwvRuIJbHadGNbFoUNKVwpRRLue6SaX0N899HZeTiTw4qHbD3hw6C9PHhxgcbiQZXl-TgJNDeusiaihqmOWbjCLOXYVVgXyEDL76fjraHw_LCCTv3slSJjFq63KIT5ptXXx92SL9BjMvo1Zvdka3_rPBt-FmwJvsbc8gd-CKbe_C9Z2won4Pvn-bTc9Of2QpPvLDTdZnU0F5jnnVNuFdluSehs1pn9GSzVpGnnp7dvoTq0R2QSPI6DQ_bfjplgzRMEN0yWZN2JDkeYAtHKMWEsb1P9dz0n0dM8R-3Trsjz7svduOwx0NsUEgJuJGytzRUmapudapLXKnC62TQhtnVVIprbh2hTCmzC0RytymolR5qrWrnOX3YaVdtPYhMNImhRRWSYWzvCyrUpVmmluEiAl3XETw6nycahMCmNM9GvO6D72c1dT82ndwBC8G2sM-bMcfqTbOh7sOooslCJEpIg2XETwfirEXaSVFtXZxTDRo1wuJpjyCBz2bDNWgxqwEzlkieO254S_117vTz1986tG_ED-DG9t7O-N6_HHy6TGsIYSreqfQBqwcdcf2CVwzJ0ezZfc0yMMvk6sUzg
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7BFlVceD8CBYzgAiI0iZ3EOSLKCsSyrBaKeotsx5ZWWrKrbMu5vwBx4Bf2lzDjuKkqEBLiEtnxJLbseXz22GOAp4VoXMGtjlOjmlg0KOlKYcool3PdpFL6m-e-TMrpVB4cVLOwN4fOwvTxIYYFN5IMr69JwO26cbtnUUNRw2xeZhRx7iJsCbpFZgRbe_Px_mRwI5C8-0WWMolRW5dDfNJs9-zr8xbpN5h5HrV6szO--p8NvgZXAt5kr3oGuQ4XbHsDtj8Ej_pN-P51MT85_pGl-MjXL1ifTQXlOeZV24R3WZJ7GrakfUYbtmgZrdTbk-OfWCWyCxpBRqf5acNPt2GIhhmiS7ZowoYkzwNs5Ri1kDCu_7leku7rmCH2627B_vjN59dv43BHQ2wQiIm4kTJ35MosNdc6tUXudKF1UmjjrEoqpRXXrhDGlLklQpnbVJQqT7V2lbP8NozaVWvvAiNtUkhhlVQ4y8uyKlVpprlFiJhwx0UEz07HqTYhgDndo7Gs-9DLWU3Nr30HR_BkoF33YTv-SLVzOtx1EF0sQYhMEWm4jODxUIy9SJ4U1drVEdGgXS8kmvII7vRsMlSDGrMSOGeJ4Lnnhr_UX8_mHz_51L1_IX4E27O9cT15N31_Hy4jgqv6NaEdGB12R_YBXDLfDheb7mEQh18D2xRJ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=miR%E2%80%9021%E2%80%905p%2C+miR%E2%80%90141%E2%80%903p%2C+and+miR%E2%80%90205%E2%80%905p+levels+in+urine%E2%80%94promising+biomarkers+for+the+identification+of+prostate+and+bladder+cancer&rft.jtitle=The+Prostate&rft.au=Ghorbanmehr%2C+Nassim&rft.au=Gharbi%2C+Sedigheh&rft.au=Korsching%2C+Eberhard&rft.au=Tavallaei%2C+Mahmood&rft.date=2019-01-01&rft.issn=0270-4137&rft.eissn=1097-0045&rft.volume=79&rft.issue=1&rft.spage=88&rft.epage=95&rft_id=info:doi/10.1002%2Fpros.23714&rft.externalDBID=10.1002%252Fpros.23714&rft.externalDocID=PROS23714
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-4137&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-4137&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-4137&client=summon